Details of the Drug Pharmacogenomic Perturbation Atlas

Raltitrexed Drug Info

Tomudex; 112887-68-0; ZD1694; ZD-1694; ICI-D1694; D-1694; ZD 1694; ICI D1694; UNII-FCB9EGG971; D1694; D 1694; CHEBI:5847; Raltitrexed (Tomudex); C21H22N4O6S; ZD-16; (2S)-2-[[5-[methyl-[(2-methyl-4-oxo-1H-quinazolin-6-yl)methyl]amino]thiophene-2-carbonyl]amino]pentanedioic acid; FCB9EGG971; CHEMBL225071; N-(5-(N-(3,4-Dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino)-2-thenoyl)-L-glutamic acid; ICI-D-1694; NSC-639186; NCGC00229704-01; DSSTox_RID_81653; DSSTox_CID_26482; DSSTox_GSID_46482

Therapeutic Class

Anticancer Agents

Cross-matching ID

PubChem CID

135400182

ChEBI ID

CHEMBL225071

CAS Number

CAS 112887-68-0

TTD Drug ID

D01KKQ

VARIDT Drug ID

DR00958

General Information of Drug (ID: DMT9K8G)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
p53 signaling pathway	2.48	0.00e+0	63/73 (86.3%)	CDKN1A;DDB2;TNFRSF10B;...
DNA replication	2.31	0.00e+0	34/36 (94.44%)	FEN1;RFC4;LIG1;...
Mismatch repair	2.17	0.00e+0	22/23 (95.65%)	RFC4;LIG1;RPA2;...
Epstein-Barr virus infection	2.09	0.00e+0	189/202 (93.56%)	CDKN1A;DDB2;FAS;...
Malaria	2.08	0.00e+0	44/50 (88%)	CXCL8;IL6;IL18;...
Influenza A	2.07	0.00e+0	156/172 (90.7%)	TNFRSF10B;FAS;CXCL8;...
Type I diabetes mellitus	2.05	0.00e+0	38/43 (88.37%)	FAS;HLA-B;HLA-DQA1;...
IL-17 signaling pathway	2.04	0.00e+0	84/94 (89.36%)	FOSL1;CXCL8;S100A8;...
Small cell lung cancer	2.01	0.00e+0	90/92 (97.83%)	CDKN1A;DDB2;CCNE2;...
Nucleotide excision repair	1.98	1.22e-3	40/47 (85.11%)	DDB2;RFC4;LIG1;...
Proteasome	1.90	6.63e-3	44/46 (95.65%)	PSMB9;PSMD14;PSMB8;...
Folate biosynthesis	1.90	7.09e-3	23/26 (88.46%)	AKR1C3;MOCOS;QDPR;...
Graft-versus-host disease	1.88	7.48e-3	32/42 (76.19%)	FAS;HLA-B;IL6;...
Pyrimidine metabolism	1.87	8.68e-3	40/56 (71.43%)	TYMS;RRM2;UPP1;...
Viral myocarditis	1.86	8.91e-3	53/60 (88.33%)	HLA-B;CXADR;HLA-DQA1;...
TNF signaling pathway	1.86	8.36e-3	103/112 (91.96%)	FAS;IL6;CXCL2;...
Viral protein interaction with cytokine and cytokine re...	1.85	8.58e-3	84/100 (84%)	TNFRSF10B;CXCL8;IL6;...
Glutathione metabolism	1.85	8.10e-3	43/57 (75.44%)	GSTM3;CHAC1;RRM2;...
Rheumatoid arthritis	1.85	7.68e-3	78/93 (83.87%)	CXCL8;IL6;IL18;...
One carbon pool by folate	1.85	7.90e-3	15/20 (75%)	TYMS;DHFR;MTHFD2;...
Cellular senescence	1.83	9.26e-3	139/156 (89.1%)	CDKN1A;CCNE2;MYBL2;...
Allograft rejection	1.83	8.84e-3	32/38 (84.21%)	FAS;HLA-B;HLA-DQA1;...
Kaposi sarcoma-associated herpesvirus infection	1.82	8.45e-3	172/193 (89.12%)	CDKN1A;FAS;HLA-B;...
Arachidonic acid metabolism	1.82	8.10e-3	48/61 (78.69%)	AKR1C3;GPX1;PTGIS;...
Fanconi anemia pathway	1.81	8.75e-3	36/54 (66.67%)	FANCI;RPA2;BRCA1;...
Pertussis	1.80	8.88e-3	64/76 (84.21%)	CXCL8;IL6;IRF8;...
Cytokine-cytokine receptor interaction	1.80	9.00e-3	246/295 (83.39%)	TNFRSF10B;FAS;CXCL8;...
Melanoma	1.80	8.68e-3	68/72 (94.44%)	CDKN1A;DDB2;PDGFA;...
Toxoplasmosis	1.79	9.64e-3	103/112 (91.96%)	PPIF;HLA-DQA1;LAMB3;...
NF-kappa B signaling pathway	1.77	9.49e-3	90/104 (86.54%)	CXCL8;CCL19;PLAU;...
GnRH secretion	-2.00	0.00e+0	60/64 (93.75%)	CACNA1G;AKT3;LHB;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	0.12uM - 10uM	6H, 24H, 48H

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.12uM - 10uM	6H, 24H, 48H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	10uM	6H

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	10uM	6H

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.12uM - 10uM	6H, 24H, 48H

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point
PC-3	CVCL_0035	Homo sapiens	1.11uM - 10uM	6H, 24H

VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	1.11uM - 10uM	6H, 24H